Then look at the Eli Lilly and Company (NYSE:LLY) share price. It's 506% higher than it was five years ago. And this is just ...

In contrast, Eli Lilly (NYSE: LLY) and Hims & Hers Health (NYSE: HIMS) both jumped on today's news. They rose 2.7% and 7%, ...

This was the stock's second consecutive day of losses.

It's hard to overstate how much demand could be out there for effective weight management drugs. The global anti-obesity drug ...

In the latest trading session, Eli Lilly (LLY) closed at $852.35, marking a -1.45% move from the previous day. The stock's performance was behind the S&P 500's daily gain of 0.16%. On the other hand, ...

Eli Lilly (NYSE: LLY) stock defied today's market ... It's as simple as that -- and good enough for a 2.6% stock price bump. Ever feel like you missed the boat in buying the most successful ...

Novo Nordisk said yesterday that it’s licensed a new obesity drug from The United Laboratories, a Chinese drugmaker.

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

Berenberg Bank analyst Kerry Holford maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on March 21 and set a price target ...

Eli Lilly (LLY) has launched its weight-loss and diabetes drug, Mounjaro (tirzepatide), in India, securing a first-mover ...

Lilly is launching two new doses and cutting prices for self-paying customers Eli Lilly & Co. said Tuesday ... alternatives to be made, sending the stock of telehealth provider Hims & Hers Health ...

Eli Lilly is buying a new drug and lowering prices ... It's as simple as that -- and good enough for a 2.6% stock price bump. Rich Smith has no position in any of the stocks mentioned.